These are the stocks posting the largest moves before the bell.Market Insiderread more
U.S. stock futures pointed to a higher open on Monday as Treasury yields rebounded to quell fears of a possible recession.US Marketsread more
The Business Roundtable, a group of CEOs of nearly 200 major U.S. corporations, gave a new definition of the "purpose of a corporation."Marketsread more
Trump said he doesn't see a recession after the bond market spooked investors and the Dow suffered its worst day of the year last week.Marketsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
Dow to jump; Trump defends economy; Huawei hopes for US reprieve; Trump and Apple's Tim Cook meet; president ties Hong Kong protests to China trade disputeMarketsread more
The U.K. prime minister prepares to meet his German and French counterparts this week.Europe Politicsread more
Amazon is raising seller fees for thousands of small and medium-sized businesses in France because of a new digital tax passed by the French government.Technologyread more
Ahead of the deadline, U.S. President Donald Trump told reporters that Huawei was a national security threat.Technologyread more
Target is launching its biggest brand yet, Good & Gather. Target expects the grocery label will be a multibillion-dollar brand by the end of 2020.Retailread more
Baidu is gearing up to release its second-quarter earnings on Monday with the market expecting a sharp decline in profit.Technologyread more
Acquisitions and breakthroughs abound in a sector brimming with options ripe for growth. Traders on CNBC's "Fast Money" outlined their strongest plays in the ever-volatile space.
"This merger party doesn't seem to be ready to die down any time soon," said trader Karen Finerman.
After enjoying a stellar 2014, funds exposed to biotech remain the "easy way out," Finerman said. The SPDR S&P Biotech ETF and iShares Nasdaq Biotechnology ETF, both up more than 25 percent in the last year, moved higher again on Monday.
The First Trust NYSE Arca Biotechnology Index Fund—which holds smaller companies in the sector—hit a 52-week high on Monday.
With stellar fund performance, individual stocks are also poised to do well, traders said. Biotech may have more room to run after some wild upward runs in 2014.
Gilead, for example, hit a snag at the end of last year amid concerns over drug prices. The stock has still gained more than 30 percent in the last year and has settled over $100 per share.
"It's right back where it should be, probably headed higher," said trader Guy Adami.
Adami will watch Agios, which is "still pretty interesting," and Celgene, which is "a name forever."